Kilitch Drugs (India) Limited (NSE:KILITCH)
India · Delayed Price · Currency is INR | Market Cap | 4.86B -1.4% |
| Revenue (ttm) | 2.07B +13.8% |
| Net Income | 264.30M +35.5% |
| EPS | 7.97 +31.4% |
| Shares Out | n/a |
| PE Ratio | 18.38 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,278 |
| Average Volume | 34,139 |
| Open | 138.00 |
| Previous Close | 138.35 |
| Day's Range | 132.20 - 139.94 |
| 52-Week Range | 117.25 - 250.00 |
| Beta | -0.24 |
| RSI | 37.02 |
| Earnings Date | May 30, 2026 |
About Kilitch Drugs (India)
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anti... [Read more]
Financial Performance
In fiscal year 2025, Kilitch Drugs (India)'s revenue was 1.98 billion, an increase of 28.47% compared to the previous year's 1.54 billion. Earnings were 267.01 million, an increase of 82.86%.
Financial StatementsNews
Kilitch Drugs India shares surge over 2% as company invests $200,000 in Kilitch Estro Biotech
Kilitch Drugs (India) Limited announced a strategic investment of $200,000 (approximately ₹1.73 crore) in its foreign subsidiary, Kilitch Estro Biotech PLC. The investment is aimed at enhancing the wo...